Autonomix Medical (NASDAQ:AMIX – Get Free Report) and iRadimed (NASDAQ:IRMD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a summary of current recommendations and price targets for Autonomix Medical and iRadimed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autonomix Medical | 1 | 1 | 1 | 0 | 2.00 |
| iRadimed | 0 | 0 | 2 | 0 | 3.00 |
Autonomix Medical currently has a consensus price target of $5.00, indicating a potential upside of 376.19%. iRadimed has a consensus price target of $72.00, indicating a potential downside of 8.06%. Given Autonomix Medical’s higher probable upside, equities analysts plainly believe Autonomix Medical is more favorable than iRadimed.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autonomix Medical | N/A | N/A | -$11.41 million | ($5.74) | -0.18 |
| iRadimed | $73.24 million | 13.60 | $19.23 million | $1.62 | 48.34 |
iRadimed has higher revenue and earnings than Autonomix Medical. Autonomix Medical is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 6.2% of Autonomix Medical shares are owned by insiders. Comparatively, 36.8% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
Autonomix Medical has a beta of -2.8, suggesting that its share price is 380% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
Profitability
This table compares Autonomix Medical and iRadimed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autonomix Medical | N/A | -172.93% | -133.39% |
| iRadimed | 26.61% | 23.30% | 20.62% |
Summary
iRadimed beats Autonomix Medical on 12 of the 13 factors compared between the two stocks.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
